Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Operations: 2015-2025

Historic Cash from Operations for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Sep 2025 value amounting to -$70.5 million.

  • Syndax Pharmaceuticals' Cash from Operations fell 13.18% to -$70.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$310.9 million, marking a year-over-year decrease of 20.09%. This contributed to the annual value of -$274.9 million for FY2024, which is 71.17% down from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Cash from Operations stood at -$70.5 million, which was up 19.66% from -$87.8 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Cash from Operations peaked at $100.7 million during Q4 2021, and registered a low of -$95.2 million during Q1 2025.
  • Over the past 3 years, Syndax Pharmaceuticals' median Cash from Operations value was -$62.3 million (recorded in 2024), while the average stood at -$62.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 744.29% in 2021, then plummeted by 122.73% in 2022.
  • Syndax Pharmaceuticals' Cash from Operations (Quarterly) stood at $100.7 million in 2021, then crashed by 122.73% to -$22.9 million in 2022, then plummeted by 80.61% to -$41.3 million in 2023, then crashed by 38.79% to -$57.4 million in 2024, then decreased by 13.18% to -$70.5 million in 2025.
  • Its Cash from Operations was -$70.5 million in Q3 2025, compared to -$87.8 million in Q2 2025 and -$95.2 million in Q1 2025.